{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "CLENE INC.", "longName": "Clene Inc.", "messageBoardId": "finmb_339429732", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChangePercent": -1.840489, "regularMarketPrice": 0.8, "marketState": "REGULAR", "firstTradeDateMilliseconds": 1611126000000, "priceHint": 4, "epsTrailingTwelveMonths": -0.41, "epsForward": -0.78, "epsCurrentYear": -1.09, "priceEpsCurrentYear": -0.73394495, "sharesOutstanding": 77494800, "bookValue": 0.043, "fiftyDayAverage": 1.0196, "fiftyDayAverageChange": -0.21960002, "fiftyDayAverageChangePercent": -0.2153786, "twoHundredDayAverage": 1.78395, "twoHundredDayAverageChange": -0.98394996, "twoHundredDayAverageChangePercent": -0.55155694, "marketCap": 64873036, "forwardPE": -1.0256411, "priceToBook": 18.60465, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "prevName": "Clene Nanomedicine Inc.", "nameChangeDate": "2023-05-11", "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "regularMarketChange": -0.014999986, "regularMarketTime": 1683875701, "regularMarketDayHigh": 0.8, "regularMarketDayRange": "0.8 - 0.8", "regularMarketDayLow": 0.8, "regularMarketVolume": 4135, "regularMarketPreviousClose": 0.815, "bid": 0.795, "ask": 0.825, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 0.8, "averageDailyVolume3Month": 89, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.0, "fiftyTwoWeekLowChangePercent": 0.0, "fiftyTwoWeekRange": "0.8 - 4.72", "fiftyTwoWeekHighChange": -3.9199998, "fiftyTwoWeekHighChangePercent": -0.8305085, "fiftyTwoWeekLow": 0.8, "fiftyTwoWeekHigh": 4.72, "earningsTimestamp": 1678705200, "earningsTimestampStart": 1684151340, "earningsTimestampEnd": 1684324140, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "symbol": "84C.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "6550 South Millrock Drive", "address2": "Suite G50", "city": "Salt Lake City", "state": "UT", "zip": "84121", "country": "United States", "phone": "801 676 9695", "website": "https://clene.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.", "fullTimeEmployees": 75, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert  Etherington MBA", "age": 55, "title": "CEO, Pres & Director", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": {"raw": 590982, "fmt": "590.98k", "longFmt": "590,982"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1130337, "fmt": "1.13M", "longFmt": "1,130,337"}}, {"maxAge": 1, "name": "Mr. Morgan R. Brown CPA, CPA, M.B.A., MBA", "age": 54, "title": "Chief Financial Officer", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 374046, "fmt": "374.05k", "longFmt": "374,046"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mark G. Mortenson ESQ.", "age": 64, "title": "Chief Science Officer", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": {"raw": 482977, "fmt": "482.98k", "longFmt": "482,977"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 584464, "fmt": "584.46k", "longFmt": "584,464"}}, {"maxAge": 1, "name": "Mr. Jerry  Miraglia J.D.", "title": "Gen. Counsel & Corp. Sec.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Michael T. Hotchkin", "title": "Chief Devel. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Mary Anne Mcneil", "title": "Head of HR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Benjamin M. Greenberg M.D., M.H.S.", "title": "Head of Medical", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}